Summit Therapeutics (SMMT) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to -$238.9 million.
- Summit Therapeutics' Enterprise Value fell 15385.77% to -$238.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$238.9 million, marking a year-over-year decrease of 15385.77%. This contributed to the annual value of -$412.3 million for FY2024, which is 12140.49% down from last year.
- Summit Therapeutics' Enterprise Value amounted to -$238.9 million in Q3 2025, which was down 15385.77% from -$298.2 million recorded in Q2 2025.
- Summit Therapeutics' 5-year Enterprise Value high stood at -$28.8 million for Q2 2024, and its period low was -$648.6 million during Q4 2022.
- Its 5-year average for Enterprise Value is -$211.6 million, with a median of -$192.6 million in 2023.
- In the last 5 years, Summit Therapeutics' Enterprise Value soared by 8662.69% in 2024 and then tumbled by 93704.18% in 2025.
- Over the past 5 years, Summit Therapeutics' Enterprise Value (Quarter) stood at -$71.8 million in 2021, then plummeted by 803.47% to -$648.6 million in 2022, then soared by 71.29% to -$186.2 million in 2023, then plummeted by 121.4% to -$412.3 million in 2024, then skyrocketed by 42.07% to -$238.9 million in 2025.
- Its Enterprise Value was -$238.9 million in Q3 2025, compared to -$298.2 million in Q2 2025 and -$361.3 million in Q1 2025.